Paul J. Hesketh MD FASCO
Chair, Lahey Cancer Institute and Professor, Medicine, UMass Chan Medical School
Join to View Full Profile
Mall Rd# 41Burlington, MA 01805
Phone+1 781-744-8400
Fax+1 781-744-5245
Dr. Hesketh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Paul J Hesketh is an oncology specialist based in Burlington, MA, with extensive experience in thoracic oncology. He completed his medical education at UCONN School of Medicine in 1978, followed by a residency in internal medicine at St Elizabeth's Medical Center in Boston and fellowships in hematology and medical oncology at Boston University Medical Center. Currently, he serves as the Director of the Sophia Gordon Cancer Center and Director of the Lahey Cancer Institute at Lahey Hospital & Medical Center and is a Professor of Medicine at UMass Chan Medical School. Dr. Hesketh has contributed numerous publications on topics such as the treatment of non-small cell lung cancer and chemotherapy-induced nausea and vomiting, and he is involved in multiple clinical trials focusing on lung cancer therapies. He has achieved CMS Meaningful Use Stage 2 certifications across various modules and systems.
Education & Training
Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1984- Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1981 - 1983
St Elizabeth's Medical CenterResidency, Internal Medicine, 1978 - 1981
Uconn School Of MedicineClass of 1978
Certifications & Licensure
FL State Medical License 2025 - Present
MA State Medical License 1980 - 2027
NH State Medical License 2024 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite (with Beaker), Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2001 Nov 01
- S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer Start of enrollment: 2004 Sep 01
- S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Dec 01
Publications & Presentations
PubMed
- Safety and efficacy of osimertinib 160 mg daily given concurrently with a strong CYP3A4 inducer.Mostafa Aglan, Erin Spyropoulous, Joel Oster, Paul J Hesketh, A J Piper-Vallillo
Respiratory Medicine Case Reports. 2025-01-01 - 19 citationsEmetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.Karin Jordan, Alexandre Chan, Richard J Gralla, Franziska Jahn, Bernardo Rapoport
Supportive Care in Cancer. 2023-12-22 - 24 citations2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.Florian Scotté, Lee Schwartzberg, Hirotoshi Iihara, Matti Aapro, Richard Gralla
Supportive Care in Cancer. 2023-12-20
Other
- Characteristics of antiemetic drugsHesketh PJ, Longstreth GF
http://www.uptodate.com/contents/characteristics-of-antiemetic-drugs
UpToDate, Wolters Kluwer Health - 2013-02-18 - Pathophysiology and prediction of chemotherapy-induced nausea and vomitingHesketh PJ
http://www.uptodate.com/contents/pathophysiology-and-prediction-of-chemotherapy-induced-nausea-and-v
UpToDate, Wolters Kluwer Health - 2012-10-01 - Prevention and treatment of chemotherapy-induced nausea and vomitingHesketh PJ
http://www.uptodate.com/contents/prevention-and-treatment-of-chemotherapy-induced-nausea-and-vomitin
UpToDate, Wolters Kluwer Health - 2013-03-08
Press Mentions
Cancer Survivorship Program Goes the Extra MileJuly 18th, 2019
Management of Chemotherapy-Induced Nausea & VomitingDecember 10th, 2017- How to Succeed in Modernizing Clinical TrialsJanuary 10th, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
